Dr. Lingkai Zhang | Cancer Immunology | Research Excellence Award

Fudan University | China

Lingkai Zhang is an M.D. candidate at Fudan University whose research focuses on cancer immunology, with a particular interest in uncovering therapeutic opportunities for urothelial carcinoma. His work centers on identifying novel immune-related mechanisms that drive disease progression, with an emphasis on single-cell RNA sequencing analysis to decode cellular heterogeneity within the tumor microenvironment. As a first or co-first author of multiple publications in high-impact peer-reviewed journals, he has contributed significantly to the understanding of natural killer cell biology in urothelial carcinoma, including the discovery of a compelling gender-specific difference in NK cell function and prognostic relevance. This discovery positions NK cells as crucial mediators of gender disparity in cancer outcomes and provides a new direction for optimizing immunotherapies, especially lymphocyte-based strategies such as CAR-NK cell treatments. Currently, he is further investigating the molecular basis and therapeutic potential of this disparity, aiming to translate immunological insights into precision oncology applications. Working closely with his supervisor and collaborating team, he actively engages in interdisciplinary discussions that support innovation and scientific rigor. Driven by a commitment to addressing unmet clinical needs, he continues to pursue impactful research that advances personalized cancer treatment and expands the frontiers of immuno-oncology.

View Scopus Profile
       View Orcid Profile

Featured Publications